bio-proteomics-ptm-analysis
Frames PTM/phosphoproteomics analysis as three stacked inference layers on a biased enrichment - chemistry selection, site localization (FLR), and protein-level-adjusted quantification with MSstatsPTM - plus kinase-activity and functional triage. Covers MaxQuant Phospho (STY)Sites multiplicity expansion, localization-probability filtering (class I, Ascore, ptmRS, DIA EG.PTMLocalizationProbabilities, DIA-NN PTM.Site.Confidence), false localization rate (LuciPHOr/DeepFLR), motif analysis with experiment-matched backgrounds, diGly/K-GG ubiquitin specificity, acetyl/glyco traps, and KSEA/PTM-SEA. Use when localizing and quantifying phosphorylation, acetylation, ubiquitination, or glycosylation sites from enrichment-based runs and deciding whether an apparent site change is real after subtracting protein abundance. Peptide ID and open/variable-mod search is peptide-identification; underlying protein-level quant is quantification and differential-abundance; DIA acquisition mechanics is dia-analysis.
- License 许可
- Apache-2.0
- 最近更新
- 2026-10-12
- Stars
- ★ 2
- Forks
- 0
01 前言 Front Matter
- name
- bio-proteomics-ptm-analysis
- tool_type
- mixed
- description
- Frames PTM/phosphoproteomics analysis as three stacked inference layers on a biased enrichment - chemistry selection, site localization (FLR), and protein-level-adjusted quantification with MSstatsPTM - plus kinase-activity and functional triage. Covers MaxQuant Phospho (STY)Sites multiplicity expansion, localization-probability filtering (class I, Ascore, ptmRS, DIA EG.PTMLocalizationProbabilities, DIA-NN PTM.Site.Confidence), false localization rate (LuciPHOr/DeepFLR), motif analysis with experiment-matched backgrounds, diGly/K-GG ubiquitin specificity, acetyl/glyco traps, and KSEA/PTM-SEA. Use when localizing and quantifying phosphorylation, acetylation, ubiquitination, or glycosylation sites from enrichment-based runs and deciding whether an apparent site change is real after subtracting protein abundance. Peptide ID and open/variable-mod search is peptide-identification; underlying protein-level quant is quantification and differential-abundance; DIA acquisition mechanics is dia-analysis.
- primary_tool
- MSstatsPTM
02 资源文件 2
- 脚本examples/phospho_analysis.py4.3 KB
- 参考文档usage-guide.md4.7 KB
03 SKILL.md 正文
Version Compatibility
Reference examples tested with: MSstatsPTM 2.8.1, MSstatsTMT 2.14.2 (the TMT route), KSEAapp 2.0, pandas 2.2+, numpy 1.26+, scipy 1.12+ (checked 2026-09-15 on R 4.4.3)
Before using code patterns, verify installed versions match. If versions differ:
- Python:
pip show <package>thenhelp(module.function)to check signatures - R:
packageVersion('<pkg>')then?function_nameto verify parameters
If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying.
PTM and Phosphoproteomics Analysis -- Three Inference Layers Stacked on a Biased Extraction
"Find the regulated phosphosites in my enriched samples" -> Localize each modification, then test whether its abundance change survives subtracting the protein-level change -- because a PTM result is three separate inferences (enrichment, localization, quantification) and each fails silently if the layer below is treated as solved.
- R:
MSstatsPTM::groupComparisonPTM()for protein-adjusted site testing (the load-bearing tool) - Python:
pandasto expand MaxQuantPhospho (STY)Sitesmultiplicity and filter localization probability - R:
KSEAapp/ PTM-SEA (ssGSEA2.0) for kinase-activity inference from the site fold-changes
Scope: this skill OWNS enrichment-chemistry framing, site localization and FLR, multiplicity-resolved site quant, protein-level adjustment (label-free AND TMT/isobaric), motif analysis, and kinase-activity inference. Peptide identification and open/variable-mod search route to peptide-identification; the underlying protein-level (unenriched) quant routes to quantification and differential-abundance; DIA acquisition mechanics route to dia-analysis. OUT OF SCOPE: intact-glycopeptide glycan-composition search (pGlyco3/MSFragger-Glyco) and absolute occupancy from three-ratio SILAC are noted but not implemented here.
The Single Most Important Modern Insight -- A PTM Result Is Three Inferences, Not One
- Enrichment IS the experiment, and the chemistry is a filter confounded with biology. The data only contain what the chemistry captured. TiO2 and Fe-IMAC give partially-overlapping phosphoproteomes; anti-K-GG enriches ubiquitin, NEDD8, and ISG15 indistinguishably; a lectin reports only its cognate glycoforms. A between-method or between-lab "biological difference" must FIRST be excluded as a chemistry artifact before it is called biology.
- Identifying a peptide is NOT localizing the modification. A phosphopeptide with two S/T and one phosphate has isobaric positional isomers of identical precursor mass and identical peptide-level score; the localization is a SECOND inference decided only by site-determining fragment ions, with its own error rate (false localization rate, FLR). Target-decoy peptide FDR cannot estimate FLR: a wrong localization is the correct sequence with the mod one residue over, not a decoy sequence (Fermin 2013). A 1% peptide FDR does NOT yield a 1% site FDR -- report them separately.
- A change in phosphopeptide abundance is NOT a change in phosphorylation (the biggest quant trap). Observed PTM signal ~ (site occupancy) x (protein abundance) x (enrichment/ionization factor), so
log2FC(PTM_observed) = log2FC(occupancy) + log2FC(protein). Without a paired global (unenriched) proteome run on the SAME samples to subtractlog2FC(protein), every protein-abundance change masquerades as a regulated site. Because co-regulated proteins move together, the false positives are pathway-coherent and look biologically convincing -- the worst kind of artifact. This is the entire reason MSstatsPTM exists (Kohler 2023). - Most identified sites have no known function. Fewer than ~5% of phosphosites are functionally annotated; a fold-change alone says nothing about regulatory relevance. Functional triage (conservation, stoichiometry, Ochoa functional score, confident kinase assignment) is a separate fourth layer on top of the quant (Ochoa 2020).
Bottom line: report THREE numbers, not one -- peptide/PSM FDR, per-site localization probability with its threshold, and an empirically estimated global FLR -- and never call a site "regulated" from a phospho-only run without protein-level adjustment.
Tool Taxonomy
Enrichment chemistry (phospho)
| Method | Citation | Mechanism / bias | When |
|---|---|---|---|
| TiO2 (MOAC) | Larsen 2005 | Metal-oxide Lewis-acid surface; skews mono-phospho; needs hydroxy-acid additive | General single-method depth; EasyPhos basis |
| Fe(III)-IMAC | Ruprecht 2015 | Chelated Fe3+ coordinates phosphate; multidentate avidity skews MULTI-phospho | Hierarchical/processive signaling; the mono/multi divergence is STRONGEST here vs TiO2 |
| Ti4+/Zr4+-IMAC | Matheron 2014 | Chelated metal ION on immobilized phosphonate (NOT bulk oxide); bias vs TiO2 is SMALL | Modern automated workflows; metal identity matters more than IMAC-vs-MOAC |
| SIMAC (sequential) | Thingholm 2008 | IMAC acidic elution = mono, basic = multi, then TiO2 on mono fraction | Recovering both populations IMAC alone biases |
Naming trap: Ti4+/Zr4+-IMAC (chelated ions) is DIFFERENT chemistry from TiO2/ZrO2 (bulk oxide). Glycolic acid is the modern additive standard (load 80% ACN / 5% TFA / 0.1 M glycolic acid).
Other-PTM enrichment and identity traps
| PTM | Reagent / mass | Citation | Headline trap |
|---|---|---|---|
| Ubiquitin (diGly, K-GG, +114.0429) | Anti-K-GG antibody | Xu 2010; Kim 2011 | NOT ubiquitin-specific: K-GG = ubiquitin + NEDD8 (~6% at basal) + ISG15 (rises under interferon). UbiSite (Akimov 2018) is the ubiquitin-specific alternative |
| Ubiquitin alkylation artifact | use chloroacetamide | Nielsen 2008 | Iodoacetamide creates a +114.0429 lysine adduct mimicking ubiquitination; chloroacetamide does not |
| Acetyl-K (+42.0106) | Anti-acetyllysine cocktail | Svinkina 2015 | Isobaric with trimethyl +42.0470 (0.0364 Da, needs high-res); acetyl blocks trypsin -> allow >=4 missed cleavages |
| Glyco N-linked | PNGase F (released) or intact | Riley 2021 | Released loses the glycan; N->D tag +0.984 is isobaric with deamidation -- use PNGase F in H2-18O (+2.988) to disambiguate; N-X-S/T (X!=Pro) sequon is necessary not sufficient |
Localization scoring
| Tool | Citation | Mechanism | Note |
|---|---|---|---|
| Ascore | Beausoleil 2006 | Cumulative binomial of site-determining ions; DIFFERENCE between best and 2nd-best localization, peak-depth sweep | Ascore >=19 ~ p 0.01 PAIRWISE per-PSM, NOT a dataset FLR |
| PhosphoRS / ptmRS | Taus 2011 | Per-isomer cumulative binomial, tolerance-aware (correct for high-res), per-site probs sum to 100% | In Proteome Discoverer |
| PTMProphet | Shteynberg (TPP) | EM/Bayesian mixture; per-site probs combinable across PSMs to a global FLR | TPP/FragPipe |
| MaxQuant Localization prob | Cox/Mann (Andromeda) | Normalized posterior on the site (fixed peak depth) | column Localization prob; >=0.75 = class I |
| DIA localization | Bekker-Jensen 2020 | XIC peak-shape correlation substitutes for missing precursor isolation | Spectronaut EG.PTMLocalizationProbabilities; DIA-NN PTM.Site.Confidence |
| DeepFLR | Zong 2023 | Deep-learning spectrum predictor + target-decoy FLR | SOTA direction; DDA + DIA |
Site-FDR / FLR (the layer most pipelines skip)
| Tool | Citation | Mechanism |
|---|---|---|
| LuciPHOr | Fermin 2013 (MCP) | Decoy localizations on non-modifiable residues; rate decoys win = empirical FLR |
| LuciPHOr2 | Fermin 2015 (Bioinformatics) | Generic-PTM successor (do NOT swap the two journals) |
| Decoy amino-acid FLR | Ramsbottom/Jones 2022 | Add a non-modifiable residue to the candidate set; global FLR ~ decoy-site-hits / target-site-hits, frequency-corrected |
Kinase-activity inference
| Tool | Citation | Mechanism | Limitation |
|---|---|---|---|
| KSEA | Casado 2013 | z-score of a kinase's substrate fold-changes | sqrt(m) favors well-annotated kinases; inherits PhosphoSitePlus bias |
| PTM-SEA / PTMsigDB | Krug 2019 | ssGSEA2.0 on site-level +/-7 flanking-sequence signatures | robust to isoform drift; PERT signatures score "looks like EGF stim" |
| RoKAI | Yilmaz 2021 | Network-smooth profiles before z-score so unobserved sites borrow neighbor signal | attacks missingness; feeds KSEA |
Benchmark result (Mueller-Dott 2025): across ~19 methods, simple z-score (KSEA/RoKAI) matched or beat sophisticated methods. Performance is PRIOR-limited, not algorithm-limited; all methods inherit PhosphoSitePlus curation bias toward CK2/CDK1/PKA/MAPK, and the dark kinome is structurally invisible. Spend effort on the substrate prior, not the estimator.
Decision Tree by Scenario
| Scenario | Recommended | Why |
|---|---|---|
| Phospho-only run, want regulated sites | Acquire a PAIRED global proteome -> MSstatsPTM groupComparisonPTM -> require significance in ADJUSTED.Model |
Unadjusted site changes are confounded with protein abundance |
| No global proteome available | Report site changes as UNADJUSTED (PTM.Model; ADJUSTED.Model is absent) and flag the confound explicitly; optionally use_unmod <- TRUE (passed as use_unmod_peptides) uses unmodified peptides co-enriched in the PTM runs as a weak protein proxy, which needs those unmodified rows kept in the evidence -- label those results proxy-adjusted |
Cannot separate occupancy from abundance; do not claim "regulation" |
| TMT / isobaric plexes (enriched + global) | Same MSstatsPTM route with labeling_type = 'TMT', dataSummarizationPTM_TMT, groupComparisonPTM(data.type = 'TMT'), and a Condition = 'Norm' reference channel in EVERY plex |
The adjustment is identical; only the converter, the summarization function and the test branch differ |
| More than one TMT plex | Refuse to compare until each plex carries the pooled reference channel; reference_norm = TRUE bridges them |
Reporter ratios are meaningful only within a plex |
| Between-method phospho difference | Suspect chemistry (TiO2 vs Fe-IMAC mono/multi bias) BEFORE biology | Enrichment is a confounded filter |
| Multiply-phospho peptides present | Localize per-site (Ascore/ptmRS) AND report empirical global FLR | Peptide FDR != site FDR |
| "Ubiquitination" sites | Confirm chloroacetamide alkylation; treat K-GG as ub + NEDD8 + ISG15; consider UbiSite | Iodoacetamide artifact + NEDD8/ISG15 confound |
| Which kinases moved? | KSEA or PTM-SEA with a curated prior; do not over-interpret dark-kinome silence | Prior-limited; simple z-score suffices |
| Motif logo from the hits | Background = experiment-matched S/T/Y from the identified proteins (NOT whole proteome) | Whole-proteome background rediscovers disordered-region composition bias |
Default when uncertain: localize with the search engine's probability (class I >=0.75), expand MaxQuant multiplicity, run MSstatsPTM with a paired global proteome, and call only ADJUSTED.Model hits regulated.
Expand the MaxQuant Site Table Before Any Quant
Goal: Produce a long, multiplicity-resolved, class-I-filtered phosphosite intensity matrix from Phospho (STY)Sites.txt.
Approach: Each site row spreads its quant across Intensity___1/___2/___3 (singly/doubly/triply-phospho forms, THREE underscores); the collapsed base Intensity mixes phospho-states and can mask a switch between forms. Per-run columns are Intensity <experiment>___<n>; the aggregated Intensity___<n> (no experiment name) is the sum over runs and must NOT be melted as a run. Drop Reverse/contaminant, filter Localization prob, then melt the per-run, per-multiplicity columns into rows.
import os
import re
import pandas as pd
import numpy as np
# Filename has a SPACE in the modification name in current MaxQuant; accept either form.
sites_file = next(f for f in ['Phospho (STY)Sites.txt', 'Phospho(STY)Sites.txt'] if os.path.exists(f))
phospho = pd.read_csv(sites_file, sep='\t', low_memory=False)
# Newer MaxQuant uses 'Potential contaminant'; older uses 'Contaminant'.
contaminant_col = 'Potential contaminant' if 'Potential contaminant' in phospho.columns else 'Contaminant'
phospho = phospho[(phospho['Reverse'] != '+') & (phospho[contaminant_col] != '+')]
CLASS_I_PROB = 0.75 # Olsen 2006 class-I convention; comparability standard, not a calibrated FLR
phospho = phospho[phospho['Localization prob'] >= CLASS_I_PROB].copy()
gene = phospho['Gene names'].where(phospho['Gene names'].notna(), phospho['Protein'])
phospho['site_id'] = gene.str.split(';').str[0] + '_' + phospho['Amino acid'] + phospho['Position'].astype(int).astype(str)
# Per-run multiplicity columns 'Intensity <run>___<n>' (THREE underscores); the space after 'Intensity'
# excludes the aggregated 'Intensity___<n>' sum-over-runs columns.
mult_cols = [c for c in phospho.columns if re.fullmatch(r'Intensity .+___[123]', c)]
long = phospho.melt(id_vars=['site_id', 'Amino acid', 'Position', 'Localization prob'], value_vars=mult_cols, var_name='run_multiplicity', value_name='intensity')
long['multiplicity'] = long['run_multiplicity'].str.split('___').str[-1]
long['run'] = long['run_multiplicity'].str.replace(r'___[123]$', '', regex=True).str.replace(r'^Intensity ', '', regex=True)
long = long[long['intensity'] > 0]
long['log2_intensity'] = np.log2(long['intensity'])
Protein-Level Adjustment with MSstatsPTM
Goal: Decide whether each site change is real after subtracting the matched protein-abundance change.
Approach: MSstatsPTM carries TWO datasets -- a PTM dataset (enriched) and a PROTEIN dataset (global/unenriched). groupComparisonPTM fits independent linear models to each and returns a list of THREE: PTM.Model (unadjusted), PROTEIN.Model, and ADJUSTED.Model. The adjustment is dFC_adj = dFC_PTM - dFC_protein with SE_adj = sqrt(SE_PTM^2 + SE_protein^2), so adjustment ADDS uncertainty -- a site can be significant unadjusted yet lose significance after adjustment. A confident regulation call requires significance in ADJUSTED.Model.
library(MSstatsPTM)
rd <- function(f) read.table(f, sep = '\t', header = TRUE, quote = '')
use_unmod <- FALSE # TRUE only when no global run exists (weak proxy, see Decision Tree)
# The converter uses the best-localized sequence as is and keeps unmodified peptides from the
# enriched runs, so apply the class-I rule to the enriched evidence FIRST: keep rows carrying the
# modification whose best site probability (from 'Phospho (STY) Probabilities') is >= 0.75.
# The use_unmod proxy needs the unmodified rows, so keep those too when it is on.
ev <- rd('evidence_phospho.txt')
site_prob <- vapply(regmatches(ev$Phospho..STY..Probabilities,
gregexpr('(?<=\\()[0-9.]+(?=\\))', ev$Phospho..STY..Probabilities, perl = TRUE)),
function(p) if (length(p)) max(as.numeric(p)) else NA_real_, numeric(1))
is_mod <- grepl('Phospho \\(STY\\)', ev$Modified.sequence)
keep <- is_mod & !is.na(site_prob) & site_prob >= 0.75
if (use_unmod) keep <- keep | !is_mod
ev <- ev[keep, ]
# Converters are <Tool>toMSstatsPTMFormat and return a list with $PTM and $PROTEIN.
# MaxQtoMSstatsPTMFormat reads the MaxQuant 'evidence.txt' (NOT the Phospho (STY)Sites
# table -- the pandas multiplicity-expansion above is a SEPARATE workflow); the FASTA maps
# peptides back to site coordinates. $PROTEIN is built ONLY when `evidence_prot` (the GLOBAL
# run's evidence) is given together with its proteinGroups and annotation.
input <- MaxQtoMSstatsPTMFormat(
evidence = ev,
annotation = read.csv('annotation_ptm.csv'),
fasta_path = 'uniprot_human.fasta',
evidence_prot = rd('evidence_global.txt'),
proteinGroups = rd('proteinGroups_global.txt'),
annotation_protein = read.csv('annotation_protein.csv'),
mod_id = '\\(Phospho \\(STY\\)\\)',
which_proteinid_ptm = 'Proteins',
which_proteinid_protein = 'Proteins',
use_unmod_peptides = use_unmod
)
stopifnot('PROTEIN' %in% names(input)) # no protein dataset -> nothing to adjust against
# append defaults to TRUE and requires a log file, so set it FALSE when use_log_file = FALSE
summarized <- dataSummarizationPTM(input, use_log_file = FALSE, append = FALSE)
# data.type is 'LabelFree' (DDA/DIA label-free) or 'TMT' -- NOT the converter's labeling_type 'LF'.
# Pass an explicit contrast: the default pairwise Label is 'Control vs Treatment' (log2FC = Control - Treatment).
# Columns must follow the sorted Condition levels.
contrast <- matrix(c(-1, 1), nrow = 1, dimnames = list('Treatment vs Control', c('Control', 'Treatment')))
result <- groupComparisonPTM(summarized, data.type = 'LabelFree', contrast.matrix = contrast)
# Three models; the adjusted one is the deliverable. Keep site rows only (Protein_<residue><position>).
adjusted <- result$ADJUSTED.Model
adjusted <- adjusted[grepl('_[STY][0-9]+', adjusted$Protein), ]
# A claim of "changed more than 2-fold" needs the threshold INSIDE the test (TREAT-style), not
# adj.pvalue < 0.05 & |log2FC| > 1 as a post-hoc double filter, whose FDR refers to log2FC != 0.
lfc <- 1
adjusted$pvalue_lfc <- pt((abs(adjusted$log2FC) - lfc) / adjusted$SE, adjusted$DF, lower.tail = FALSE)
adjusted$adj.pvalue_lfc <- p.adjust(adjusted$pvalue_lfc, method = 'BH')
regulated <- adjusted[!is.na(adjusted$adj.pvalue_lfc) & adjusted$adj.pvalue_lfc < 0.05, ]
# How much of each call was protein-driven: compare PTM.Model vs ADJUSTED.Model.
TMT / isobaric plexes -- same adjustment, three different calls
Goal: The same protein-adjusted site testing when the enriched and global runs are isobaric-labelled plexes (the dominant platform for large-cohort phosphoproteomics).
Approach: Only three things change. labeling_type = 'TMT' on the converter (default 'LF'), dataSummarizationPTM_TMT instead of dataSummarizationPTM -- a different FUNCTION, not a flag -- and data.type = 'TMT' in groupComparisonPTM. The annotation is the MSstatsTMT one: Run, Fraction, TechRepMixture, Channel, Condition, Mixture, BioReplicate (Raw.file is also accepted). Mismatching the two halves fails loudly in BOTH directions, but neither message says "wrong labeling type": a label-free annotation with labeling_type = 'TMT' gives Extra columns included in the annotation file that are not required ... Run, Raw.file, Fraction, TechRepMixture, Channel, Condition, Mixture, BioReplicate -- read that list as the spec for the TMT annotation -- and TMT evidence left on the default 'LF' gives the much less obvious A non-empty vector of column names for 'by' is required. EVERY plex needs a pooled reference channel carried as Condition = 'Norm'; reference_norm = TRUE (default) uses it to put plexes on a common scale -- the IRS bridge -- and remove_norm_channel = TRUE (default) drops it before testing. Without one, cross-plex comparison is invalid and no amount of downstream modelling repairs it.
Two TMT-specific traps for the ADJUSTMENT itself, not just for the quant:
- Ratio compression biases the subtraction, it does not merely attenuate it. Co-isolated precursors pull every reporter ratio toward 1, and the PTM and PROTEIN datasets are not compressed equally -- enriched phosphopeptide runs are a sparser, differently-interfered precursor space than the global run. So
dFC_adj = dFC_PTM - dFC_proteinsubtracts two differently-shrunken numbers. Use MS3/SPS or FAIMS to reduce it, and read TMT effect sizes as lower bounds; the SIGN and ranking survive, the magnitude does not. - Label the enriched and global aliquots in the SAME plex where the design allows. Split across plexes, each dataset carries its own reference-channel normalization and the site-to-protein subtraction inherits both.
library(MSstatsPTM)
rd <- function(f) read.table(f, sep = '\t', header = TRUE, quote = '')
# Class-I pre-filter on the ENRICHED evidence, exactly as in the label-free route above.
ev <- rd('evidence_phospho_tmt.txt')
site_prob <- vapply(regmatches(ev$Phospho..STY..Probabilities,
gregexpr('(?<=\\()[0-9.]+(?=\\))', ev$Phospho..STY..Probabilities, perl = TRUE)),
function(p) if (length(p)) max(as.numeric(p)) else NA_real_, numeric(1))
ev <- ev[grepl('Phospho \\(STY\\)', ev$Modified.sequence) & !is.na(site_prob) & site_prob >= 0.75, ]
# TMT annotation: Run, Fraction, TechRepMixture, Channel, Condition, Mixture, BioReplicate.
# Channel is 'channel.1' ... 'channel.N' and maps to the evidence's
# 'Reporter intensity corrected <n>' columns; the CORRECTED ones, not the raw reporters.
# Give the pooled reference channel Condition = 'Norm' in EVERY plex.
input <- MaxQtoMSstatsPTMFormat(
evidence = ev,
annotation = read.csv('annotation_ptm_tmt.csv'),
fasta_path = 'uniprot_human.fasta',
evidence_prot = rd('evidence_global_tmt.txt'),
proteinGroups = rd('proteinGroups_global.txt'),
annotation_protein = read.csv('annotation_protein_tmt.csv'),
labeling_type = 'TMT', # the single converter switch; default is 'LF'
mod_id = '\\(Phospho \\(STY\\)\\)',
which_proteinid_ptm = 'Proteins',
which_proteinid_protein = 'Proteins',
use_unmod_peptides = FALSE)
stopifnot('PROTEIN' %in% names(input))
# TMT summarization is its own function. reference_norm / reference_norm.PTM (default TRUE) apply
# the 'Norm'-channel bridge; remove_norm_channel (default TRUE) drops that channel afterwards, so
# the contrast below names only the biological conditions.
summarized <- dataSummarizationPTM_TMT(input, use_log_file = FALSE, append = FALSE)
contrast <- matrix(c(-1, 1), nrow = 1, dimnames = list('Treatment vs Control', c('Control', 'Treatment')))
result <- groupComparisonPTM(summarized, data.type = 'TMT', contrast.matrix = contrast)
adjusted <- result$ADJUSTED.Model
adjusted <- adjusted[grepl('_[STY][0-9]+', adjusted$Protein), ]
# From here the TREAT-style threshold, the PTM.Model-vs-ADJUSTED.Model comparison and the KSEA
# block below are identical to the label-free route -- only the three calls above differ.
Starting from Phospho (STY)Sites.txt instead of evidence.txt (the sites_data = argument) is the one place TMT_keyword matters: there the converter builds column names as Reporter.intensity.corrected.<n>.<TMT_keyword><mixture>, so TMT_keyword must match how the site table's reporter columns were named. It is ignored on the evidence = route shown above.
Motif Analysis with the Correct Background
Goal: Find kinase/writer motifs around the modified residue without rediscovering amino-acid composition bias.
Approach: Use the Sequence window (+/-15 residues, 31-mer) MaxQuant already provides, centered on the site. The background MUST be an experiment-matched S/T/Y set drawn from the identified proteins (or a central-residue-preserving shuffle), NOT the whole proteome or IUPAC-random -- those just report the composition of phospho-rich disordered regions. motif-x and MoMo p-values are only valid when the background is built this way.
from collections import Counter
import pandas as pd
from scipy.stats import fisher_exact, false_discovery_control
# 'Sequence window' is a 31-mer (+/-15) centered on the modified residue.
WINDOW_HALF = 7 # +/-7 flanking is the standard kinase-motif window
# foreground: e.g. the regulated-up class-I sites; here all class-I sites from the expansion block
foreground = [w[15 - WINDOW_HALF: 16 + WINDOW_HALF] for w in phospho['Sequence window'].dropna() if len(w) >= 31]
def matched_background(fasta, accessions, residues='ST'):
'''Every S/T (or Y) window in the IDENTIFIED proteins, central residue preserved.
fasta: {accession: sequence}; accessions: proteins identified in this experiment.'''
windows = []
for acc in accessions:
seq = fasta[acc]
for i, aa in enumerate(seq):
if aa in residues:
windows.append(''.join(seq[j] if 0 <= j < len(seq) else '_' for j in range(i - WINDOW_HALF, i + WINDOW_HALF + 1)))
return windows
def position_frequencies(windows):
counts = {i: Counter() for i in range(-WINDOW_HALF, WINDOW_HALF + 1)}
for w in windows:
for offset, aa in zip(range(-WINDOW_HALF, WINDOW_HALF + 1), w):
if aa not in '_X':
counts[offset][aa] += 1
return counts
def motif_enrichment(fg_windows, bg_windows):
'''One-sided Fisher test per (position, residue), BH-adjusted across all tests.'''
fg, bg = position_frequencies(fg_windows), position_frequencies(bg_windows)
rows = []
for offset in fg:
if offset == 0:
continue
n_fg, n_bg = sum(fg[offset].values()), sum(bg[offset].values())
for aa, k in fg[offset].items():
_, p = fisher_exact([[k, n_fg - k], [bg[offset][aa], n_bg - bg[offset][aa]]], alternative='greater')
rows.append({'offset': offset, 'aa': aa, 'fg': k, 'fg_total': n_fg, 'bg': bg[offset][aa], 'bg_total': n_bg, 'p': p})
table = pd.DataFrame(rows)
table['q'] = false_discovery_control(table['p'], method='bh')
return table.sort_values('p')
For a publication-grade enrichment logo, hand the foreground and a matched background to a dedicated tool (motif-x / MoMo) and render with data-visualization/sequence-logos.
Kinase Activity with KSEAapp
Goal: Score kinase activity from the protein-adjusted site fold-changes.
Approach: KSEAapp::KSEA.Scores merges the site table with a kinase-substrate prior on gene symbol + residue and returns a z-score per kinase with its substrate count m. The prior (KSData: PhosphoSitePlus + NetworKIN table with KINASE, SUB_GENE, SUB_MOD_RSD, Source, networkin_score columns) must be the full file from github.com/casecpb/KSEA; the package's data(KSData) is an abbreviated demonstration subset. PX needs six columns in this exact order, and FC is a LINEAR ratio (the function takes log2 itself), treatment over control.
library(KSEAapp)
KSData <- read.csv('PSP&NetworKIN_Kinase_Substrate_Dataset.csv') # user-supplied prior
pg <- rd('proteinGroups_global.txt')
gene_symbol <- setNames(sub(';.*', '', pg$Gene.names), sub(';.*', '', pg$Protein.IDs))
# log2FC = +/-Inf (site measured in one condition only) gives FC = 0 or Inf, and one such row
# turns every kinase z-score NaN; filter on log2FC, not on the linear FC (0 is finite)
ks <- adjusted[is.finite(adjusted$log2FC), ]
if (nrow(ks) == 0)
stop('No site has a finite log2FC -- every row of the adjusted table is +/-Inf or NA, i.e. every ',
'site was quantified in one condition only. KSEA scores fold changes, not presence/absence; ',
'report those sites as detected-in-one-condition instead.')
PX <- data.frame(
Protein = sub('_[STY][0-9]+$', '', ks$Protein),
Gene = gene_symbol[sub('_[STY][0-9]+$', '', ks$Protein)], # HUGO symbol; merge key with SUB_GENE
Peptide = rep('NULL', nrow(ks)), # rep(), not the bare literal: a length-1 value against
# zero-length columns is 'differing number of rows: 0, 1'
Residue.Both = sub('^.*_', '', ks$Protein), # e.g. S473; merge key with SUB_MOD_RSD
p = ks$adj.pvalue,
FC = 2^ks$log2FC) # Treatment/Control because the contrast above is 'Treatment vs Control'
PX <- PX[!is.na(PX$Gene), ]
if (nrow(PX) == 0)
stop('PX is empty after dropping sites with no gene symbol: proteinGroups_global.txt carried no ',
'`Gene names` for any tested protein. Check the search FASTA had gene annotation, or map the ',
'accessions to HUGO symbols yourself before building PX.')
# Check PRIOR COVERAGE before calling. KSEA.Scores merges on SUB_GENE + SUB_MOD_RSD and then
# aggregates, so a prior overlapping this site list in 0 or 1 place dies inside the package with
# `no rows to aggregate` -- a message that says nothing about coverage. Curated priors cover only a
# small fraction of any real site list, so this is the common failure, not an exotic one.
prior <- KSData[grep('PhosphoSitePlus', KSData$Source), ] # the subset NetworKIN = FALSE will use
covered <- sum(paste(PX$Gene, PX$Residue.Both) %in% paste(prior$SUB_GENE, prior$SUB_MOD_RSD))
cat('sites in PX:', nrow(PX), '| covered by the prior:', covered, '\n')
if (covered < 2)
stop('The kinase-substrate prior covers ', covered, ' of ', nrow(PX), ' sites, so KSEA has ',
'nothing to score. Check that KSData is the FULL PhosphoSitePlus+NetworKIN table (not the ',
'abbreviated data(KSData)), that Gene holds HUGO symbols matching SUB_GENE, and that ',
'Residue.Both is formatted like SUB_MOD_RSD (S473, not pS473 or Ser473).')
# NetworKIN = FALSE: PhosphoSitePlus-curated pairs only; TRUE adds predictions above NetworKIN.cutoff
# (and then coverage should be counted against that subset instead).
kinase_scores <- KSEA.Scores(KSData, PX, NetworKIN = FALSE, NetworKIN.cutoff = 3)
kinase_scores[order(kinase_scores$z.score), c('Kinase.Gene', 'm', 'z.score', 'FDR')]
If the contrast Label reads Control vs Treatment, use FC = 2^(-log2FC), or every kinase's sign inverts.
A Note on Home-Grown Ascore
The function below is an ILLUSTRATIVE approximation, NOT real Ascore. Real Ascore (Beausoleil 2006) competes the best localization against the second-best, sweeps peak depth 1-10 per 100 Th, and restricts to site-determining ions -- none of which this captures. Use the search engine's own localization probability (MaxQuant Localization prob, ptmRS, PTMProphet) for real work, or pyOpenMS AScore (introspect the exact API before relying on it). The home-grown form is here only to show the binomial intuition.
import numpy as np
from scipy.stats import binom
def illustrative_localization_score(matched_site_ions, total_ions, depth_p=0.04):
'''Binomial intuition only; NOT Ascore (no best-vs-second competition or depth sweep).'''
if total_ions == 0 or matched_site_ions == 0:
return 0.0
p_random = 1 - binom.cdf(matched_site_ions - 1, total_ions, depth_p)
return -10 * np.log10(p_random) if p_random > 0 else 100.0
Per-Method Failure Modes
Skipping protein-level adjustment
Trigger: Differential testing on a phospho-only run with no paired global proteome. Mechanism: log2FC(PTM_observed) = log2FC(occupancy) + log2FC(protein); the two terms are inseparable. Symptom: Pathway-coherent "regulated sites" that are pure protein-abundance changes (cyclins/histones in cell cycle, stabilized substrates under drug). Fix: Run a matched global proteome and adjust via MSstatsPTM; route the protein-level quant to quantification.
Collapsing the MaxQuant multiplicity
Trigger: Quantifying on base Intensity instead of Intensity___1/___2/___3. Mechanism: The collapsed column mixes singly/doubly/triply-phospho forms of the same site. Symptom: A switch between forms is masked: the singly-phospho form dropping while the doubly-phospho form rises reads as no change (synthetic test: collapsed +0.16 log2, ___1 -1.40, ___2 +1.56). Fix: Expand multiplicity to long form (Perseus "Expand site table" or the melt above) before any stats.
Treating identification as localization
Trigger: Reporting sites at peptide FDR without a localization threshold. Mechanism: Isobaric positional isomers share precursor mass and peptide score; CID/ion-trap neutral loss (-98 Da) starves site-determining ions. Symptom: A 1% peptide FDR result with a much higher true site error. Fix: Filter localization probability (class I >=0.75) in EVERY route, including the evidence fed to MSstatsPTM; report an empirical global FLR (LuciPHOr2/DeepFLR), prefer HCD/EThcD. Empirical FLR needs the spectra (mzML); from MaxQuant txt tables alone, report only the model-based expected FLR mean(1 - Localization prob) over the accepted sites and label it as such -- it misses mis-assignment sources the search model does not know about.
diGly read as ubiquitin
Trigger: Calling the K-GG proteome "ubiquitination". Mechanism: NEDD8 and ISG15 share the LRLRGG C-terminus and leave the identical +114.0429 remnant; iodoacetamide adds a fourth source. Symptom: Inflated/false ubiquitin sites, worst under interferon (ISG15) or with iodoacetamide. Fix: Ask which alkylation reagent was used; chloroacetamide for future experiments; treat K-GG as ub+NEDD8+ISG15; use UbiSite for ubiquitin-specific mapping. For data already acquired, flag K-GG on the peptide C-terminal lysine (a GG-modified K blocks trypsin, so a C-terminal GG-K is suspect): ev['Modified sequence'].str.contains(r'K\(GlyGly \(K\)\)_$').
Motif logo against the wrong background
Trigger: Whole-proteome or IUPAC-random background. Mechanism: Phosphosites sit in disordered, Ser/Pro/acidic-rich regions; that composition dominates the enrichment. Symptom: "Enriched" proline/serine motifs that are region bias, not kinase preference. Fix: Experiment-matched S/T/Y background or central-residue-preserving shuffle (MoMo default).
Over-reading kinase-activity output
Trigger: Naming the top KSEA/atlas kinase as the responsible enzyme. Mechanism: Substrate priors are PhosphoSitePlus-curated (CK2/CDK1/PKA/MAPK heavy); atlas hits are biochemical preference ignoring expression/localization/timing. Symptom: Always-the-usual-suspects kinase lists; dark-kinome activity invisible. Fix: Use a curated prior, report z-scores with their substrate counts, do not infer absence from silence.
Quantitative Thresholds
| Threshold | Source | Rationale |
|---|---|---|
| Localization prob class I >= 0.75 | Olsen 2006 | Best site holds >3x the posterior of all alternatives (single-phospho); a comparability standard, not a calibrated error rate |
| Class II 0.5-0.75; class III 0.25-0.5 | Olsen 2006 | Partial / poor localization |
| Ascore >= 19 (p~0.01); loose >13 | Beausoleil 2006 | Pairwise per-PSM best-vs-next confidence; NOT a dataset FLR |
| DIA directDIA localization >= 0.99 | Bekker-Jensen 2020 | Stricter than library-based (0.75) to match DDA error rates |
| DIA-NN site matrix 0.90 / 0.99 | DIA-NN docs | phosphosites_90/99.tsv; class-I-equivalent stringency is HIGHER than MaxQuant 0.75 |
| Acetyl missed cleavages >= 4 | -- | Acetyl-K blocks trypsin; pair LysC + trypsin |
| Kinase atlas motif match >= 90th percentile | Johnson 2023 | Strong motif preference, NOT proof the kinase acted |
| Report peptide FDR and site FLR separately | Fermin 2013 | 1% peptide FDR != 1% site FDR; true site error is typically several-fold higher |
Common Errors
| Error / symptom | Cause | Solution |
|---|---|---|
| FileNotFoundError on the sites table | Filename has a SPACE: Phospho (STY)Sites.txt |
Accept either spaced or no-space form |
| Form switch hidden (no change on a site that switched singly/doubly) | Quantified base Intensity, mixing multiplicities |
Use Intensity <run>___1/___2/___3 (three underscores) |
Extra "run" named Intensity in the long table, ~2.7 log2 above the others |
Melt also matched the aggregated Intensity___1/2/3 columns |
Select Intensity <run>___n (note the space) |
Assertion on '!(append & !use_log_file)' failed |
dataSummarizationPTM defaults append = TRUE |
dataSummarizationPTM(input, use_log_file = FALSE, append = FALSE) |
object 'ptm_model' not found in groupComparisonPTM |
data.type = 'LF' matches neither branch |
data.type = 'LabelFree' (or 'TMT') |
Extra columns included in the annotation file that are not required ... Run, Raw.file, Fraction, TechRepMixture, Channel, Condition, Mixture, BioReplicate |
a label-free annotation passed with labeling_type = 'TMT' |
Use the TMT annotation columns the message itself lists |
A non-empty vector of column names for 'by' is required from MaxQtoMSstatsPTMFormat |
TMT evidence left on the default labeling_type = 'LF'; the message never mentions labeling |
labeling_type = 'TMT', then dataSummarizationPTM_TMT and data.type = 'TMT' |
names(input) is only PTM; ADJUSTED.Model missing |
evidence_prot not passed to MaxQtoMSstatsPTMFormat |
Pass the global run's evidence as evidence_prot; stopifnot('PROTEIN' %in% names(input)) |
z.score NaN for every kinase from KSEA.Scores |
a site with log2FC -Inf/Inf (missing in one condition) entered PX; FC = 0 passes is.finite(FC) |
drop rows with non-finite log2FC before building PX |
arguments imply differing number of rows: 0, 1 while building PX |
the non-finite-log2FC filter emptied the table, and Peptide = 'NULL' is a length-1 literal against zero-length columns |
guard nrow(ks) == 0 with a message about one-condition sites, and use rep('NULL', nrow(ks)) |
no rows to aggregate from KSEA.Scores |
the prior overlaps the site list in 0 or 1 place -- usually the abbreviated data(KSData), a non-HUGO Gene column, or residues written pS473/Ser473 |
count paste(Gene, Residue.Both) against paste(SUB_GENE, SUB_MOD_RSD) before calling and stop with the coverage number |
Can't assign 4 names to a 0-column data.table with use_unmod_peptides = TRUE |
the evidence pre-filter removed every unmodified row | set use_unmod <- TRUE so unmodified rows are kept; the class-I rule applies to modified rows only |
| Site signs inverted in KSEA / up-down calls | Default pairwise Label Control vs Treatment means log2FC = Control - Treatment |
Check adjusted$Label or pass an explicit contrast.matrix |
Protein names without a site suffix in ADJUSTED.Model |
Unmodified peptides from the enriched runs entered $PTM |
Pre-filter evidence to modified rows; drop rows without _<residue><position> |
KeyError / NaN on Gene names |
Column is FASTA-dependent, absent without gene annotation | Guard with .notna() and fall back to Protein |
| All sites "regulated" and pathway-coherent | No protein-level adjustment | Require significance in MSstatsPTM ADJUSTED.Model |
PTM.Q.Value / PhosphoSite not found (DIA-NN) |
Those columns do not exist | Use PTM.Site.Confidence and Site.Occupancy.Probabilities |
| False "ubiquitination" sites | Iodoacetamide +114.0429 lysine artifact | Alkylate with chloroacetamide |
| Acetyl confused with trimethyl | +42.0106 vs +42.0470 isobaric at nominal mass | Require high-res MS; check 0.0364 Da split |
References
- Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 2006;24(10):1285-1292.
- Taus T, Kocher T, Pichler P, et al. Universal and confident phosphorylation site localization using phosphoRS. J Proteome Res 2011;10(12):5354-5362.
- Olsen JV, Blagoev B, Gnad F, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006;127(3):635-648.
- Fermin D, Walmsley SJ, Gingras AC, Choi H, Nesvizhskii AI. LuciPHOr: algorithm for phosphorylation site localization with false localization rate estimation using modified target-decoy approach. Mol Cell Proteomics 2013;12(11):3409-3419.
- Fermin D, Avtonomov D, Choi H, Nesvizhskii AI. LuciPHOr2: site localization of generic PTMs from tandem mass spectrometry data. Bioinformatics 2015;31(7):1141-1143.
- Bekker-Jensen DB, Bernhardt OM, Hogrebe A, et al. Rapid and site-specific deep phosphoproteome profiling by data-independent acquisition without the need for spectral libraries. Nat Commun 2020;11:787.
- Kohler D, Tsai TH, Verschueren E, et al. MSstatsPTM: Statistical Relative Quantification of Posttranslational Modifications in Bottom-Up Mass Spectrometry-Based Proteomics. Mol Cell Proteomics 2023;22(1):100477.
- Ochoa D, Jarnuczak AF, Vieitez C, et al. The functional landscape of the human phosphoproteome. Nat Biotechnol 2020;38(3):365-373.
- Casado P, Rodriguez-Prados JC, Cosulich SC, et al. Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells. Sci Signal 2013;6(268):rs6.
- Krug K, Mertins P, Zhang B, et al. A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell Proteomics 2019;18(3):576-593.
- Yilmaz S, Ayati M, Schlatzer D, et al. Robust inference of kinase activity using functional networks. Nat Commun 2021;12:1177.
- Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, Jorgensen TJD. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics 2005;4(7):873-886.
- Ruprecht B, Koch H, Medard G, et al. Comprehensive and reproducible phosphopeptide enrichment using iron immobilized metal ion affinity chromatography (Fe-IMAC) columns. Mol Cell Proteomics 2015;14(1):205-215.
- Matheron L, van den Toorn H, Heck AJR, Mohammed S. Characterization of biases in phosphopeptide enrichment by Ti(IV)-IMAC and TiO2 using a massive synthetic library and human cell digests. Anal Chem 2014;86(16):8312-8320.
- Thingholm TE, Jensen ON, Robinson PJ, Larsen MR. SIMAC (sequential elution from IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Mol Cell Proteomics 2008;7(4):661-671.
- Svinkina T, Gu H, Silva JC, et al. Deep, Quantitative Coverage of the Lysine Acetylome Using Novel Anti-acetyl-lysine Antibodies and an Optimized Proteomic Workflow. Mol Cell Proteomics 2015;14(9):2429-2440.
- Xu G, Paige JS, Jaffrey SR. Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. Nat Biotechnol 2010;28(8):868-873.
- Kim W, Bennett EJ, Huttlin EL, et al. Systematic and Quantitative Assessment of the Ubiquitin-Modified Proteome. Mol Cell 2011;44(2):325-340.
- Nielsen ML, Vermeulen M, Bonaldi T, Cox J, Moroder L, Mann M. Iodoacetamide-induced artifact mimics ubiquitination in mass spectrometry. Nat Methods 2008;5(6):459-460.
- Akimov V, Barrio-Hernandez I, Hansen SVF, et al. UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 2018;25(7):631-640.
- Riley NM, Bertozzi CR, Pitteri SJ. A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry-Based Glycoproteomics. Mol Cell Proteomics 2021;20:100029.
- Johnson JL, Yaron TM, Huntsman EM, et al. An atlas of substrate specificities for the human serine/threonine kinome. Nature 2023;613(7945):759-766.
- Mueller-Dott S, Jaehnig EJ, et al. Comprehensive evaluation of phosphoproteomic-based kinase activity inference. Nat Commun 2025;16:4771.
- Zong Y, Wang Y, Yang Y, et al. DeepFLR facilitates false localization rate control in phosphoproteomics. Nat Commun 2023;14:2269.
- Ramsbottom KA, Prakash A, Riverol YP, et al. Method for independent estimation of the false localization rate for phosphoproteomics. J Proteome Res 2022;21(7):1603-1615.
Related Skills
- peptide-identification - Identify modified peptides and run open/variable-mod search
- quantification - Underlying protein-level quant feeding the MSstatsPTM PROTEIN dataset
- differential-abundance - Moderated testing on the protein-level intensity matrix
- pathway-analysis/gsea - Enrichment scoring of regulated-site protein lists and PTM-SEA-style signatures
- data-visualization/sequence-logos - Render motif logos from the foreground/background windows
04 同仓库更多 Skills
bio-workflows-metabolomics-pipeline
Orchestrates the untargeted LC-MS metabolomics pipeline end-to-end (xcms 4.x feature extraction, QC/drift/normalization, confidence-stratified annotation, permutation-validated statistics, background-aware pathway mapping), naming what each stage decides and where it silently fails. Use when running a full LC-MS metabolomics study from raw mzML to enriched pathways and needing the honest handoffs between stages. Each stage defers to its component skill for parameters and traps; for stable-isotope flux (a separate branch, not this untargeted flow) see metabolomics/isotope-tracing.
bio-metabolomics-xcms-preprocessing
Programmatic untargeted LC-MS feature extraction in R with the modern xcms 4.x MsExperiment/XcmsExperiment API, taking raw mzML to a feature table via CentWave peak detection, retention-time alignment, peak-density correspondence, gap-filling, CAMERA redundancy collapse, and built-in QC feature filtering. Use when converting centroided LC-MS runs into a features-by-samples matrix and deciding centWave/grouping/alignment parameters. For drift correction and QC/CV filtering execution see metabolomics/normalization-qc; for metabolite identification see metabolomics/metabolite-annotation; for the MS-DIAL GUI alternative with MS2Dec deconvolution see metabolomics/msdial-preprocessing; for downstream statistics see metabolomics/statistical-analysis.
bio-metabolomics-statistical-analysis
Decision-grade statistical analysis for metabolomics intensity tables. Covers transformation and scaling (Pareto vs unit-variance as a hidden hypothesis), unsupervised structure (PCA/HCA for QC), permutation-validated PLS-DA/OPLS-DA (R2 vs Q2, double CV, VIP as heuristic), univariate testing (Welch/Mann-Whitney/ANOVA/LMM with covariate adjustment), and dependence-aware multiple testing. Use when testing which metabolites differ, building or validating a discriminant model, choosing a scaling, or correcting many correlated tests. For sample-wise normalization/drift correction see metabolomics/normalization-qc; for ML classifiers and selection-inside-CV leakage see machine-learning/biomarker-discovery and machine-learning/model-validation; for pathway interpretation see metabolomics/pathway-mapping; for design/power/multiplicity regime see experimental-design/multiple-testing.
bio-metabolomics-pathway-mapping
Maps metabolomics results to biological pathways via over-representation (ORA), metabolite-set enrichment (MSEA/QEA), mummichog/PSEA on raw m/z peaks, and network-diffusion enrichment (FELLA), with correct background-set construction and honest interpretive ceilings. Use when interpreting differential metabolites or an untargeted LC-MS feature table in pathway context, choosing ORA vs MSEA vs mummichog vs topology, or setting the reference/background set. For annotation confidence levels feeding ORA see metabolomics/metabolite-annotation; for gene-set concepts see pathway-analysis/go-enrichment and pathway-analysis/gsea; for joint gene+metabolite pathways see multi-omics-integration/mofa-integration.
bio-metabolomics-normalization-qc
Designs QC, corrects signal drift, removes batch effects, filters features, normalizes samples, and imputes missing values for untargeted LC-MS/GC-MS metabolomics, framing each step as a measurement model that can create or erase biological signal. Use when processing a peak/feature table before statistical analysis, choosing a drift-correction or sample-normalization method, deciding QC RSD vs D-ratio filtering, or handling left-censored missing values. The feature table is produced by metabolomics/xcms-preprocessing or metabolomics/msdial-preprocessing; transformation/scaling for modeling defers to metabolomics/statistical-analysis; cross-study design issues link to experimental-design/batch-design.
bio-metabolomics-msdial-preprocessing
Runs the MS-DIAL preprocessing workflow (peak picking, MS2Dec spectral deconvolution, alignment, gap-filling) and imports the alignment-result table into R or Python with honest filtering. Use when preprocessing LC-MS DDA/DIA (SWATH) or GC-MS raw data with MS-DIAL, deciding MS-DIAL vs XCMS, configuring the MSDIALCUI console run, or parsing an MS-DIAL export into a clean feature matrix. For programmatic R peak detection and the feature-table-as-artifact framing see metabolomics/xcms-preprocessing; for lipid annotation mode see metabolomics/lipidomics; for MSI-level confidence honesty see metabolomics/metabolite-annotation; for drift correction and QC see metabolomics/normalization-qc.